Pre-

clinical

IND

Clinical

  Trial

NDA

I

II

III

CNS

Rasa-

giline

trans-

dermal

patch

II

MAO-B

inhibitor

Parkinson

(1)first

sustained

release

formulation

of

Rasagiline

(2) market

exclusivity

(3) once

every 3

days,good

compliance.

Tumor

targeted

therapy

1

1

Cellular

stress

responsive

inhibitor

Triplene-

gative

breast

cancer

First-

in-class

2

1

BTK

inhibitor

B cell

associated

lymphoma

Me-better

3

1

PARP

inhibitor

Ovarian

cancer

Me-better

4

1

Cell

metabolic

inhibitor

Cancer

First-

in-class

Tumor

immune

therapy

5

1

Inhibitor

containing

PD-L1

Caner

Small

molecular,

First-

in-class

6

1

Immune

escape

inhibitor

Caner

Small

molecular,

First-

in-class